JOLIMARK(02028)

Search documents
2025年中国喷墨打印机行业发展历程、产业链图谱、出货量、重点企业及发展趋势研判:喷墨打印机市场有望回暖,消费复苏和技术创新将推动出货量回升[图]
Chan Ye Xin Xi Wang· 2025-05-27 01:37
Core Insights - The inkjet printer market in China is experiencing a decline due to economic fluctuations, budget tightening, and consumer downgrade, with a projected shipment volume of 7.292 million units in 2024, representing an 8.7% year-on-year decrease [1][15][13] - Despite the overall decline, there is an anticipated recovery in demand in the second half of 2024, particularly driven by back-to-school season and the increasing importance of printers among students [1][15] - The market is expected to benefit from the continuous innovation in inkjet technology and an improvement in the economic environment, leading to a potential rebound in shipment volumes [1][15] Industry Overview - Inkjet printers are non-contact printers that recreate digital images by pushing ink droplets through nozzles onto paper and plastic substrates [1][15] - The technology includes ion ink, which is guided by a magnetic plate to spray onto paper, and is utilized across various industries such as advertising, textiles, packaging, education, and pharmaceuticals [1][15] - The classification of inkjet printers can be based on various factors including maximum print width, ink cartridge type, and whether they support network printing [4][5] Market Trends - The inkjet printer market in China saw a steady increase in shipments from 2017 to 2022, but has faced a downturn from 2023 to 2024 [1][15] - The overall printer market in China is projected to have a total shipment volume of 15.308 million units in 2024, with inkjet printers becoming the largest category, surpassing laser printers [13][15] - The market size for inkjet printers in China is estimated to be around $704 million in 2024, reflecting a shift towards inkjet technology due to its advantages in small batch printing and color output [16] Competitive Landscape - The competitive landscape of the inkjet printer market in China is characterized by a dual-track system where foreign companies dominate the high-end market while local companies are emerging through differentiated innovation [18][20] - Major international players include Epson, HP, Canon, and Brother, while local companies like Honghua Digital and Xiaomi are expanding their market presence [18][20] - The industry is witnessing a trend towards green and smart products, with a focus on low-energy consumption and recyclable materials, as well as the integration of IoT technologies for remote management and cloud printing [26][27] Future Outlook - The demand for inkjet printers is expected to continue growing due to the acceleration of digital transformation, with increasing needs from home offices, online education, and small businesses [25] - The commercial market for inkjet printers is projected to expand further, driven by the demand for short-run printing and personalized packaging [27] - The trend towards green and intelligent products will shape the future of the inkjet printer market, with a focus on sustainable practices and advanced technology integration [26][27]
映美控股(02028) - 2024 - 年度财报
2025-04-28 09:06
Financial Performance - The company reported revenue of approximately RMB 149,737,000 for 2024, a decrease of about 26% compared to 2023, with a net loss attributable to shareholders of approximately RMB 59,834,000[7]. - For the year ended December 31, 2024, the group's revenue was approximately RMB 149,737,000, a decrease of about 26% compared to the previous year[17]. - The loss attributable to shareholders was approximately RMB 59,834,000, a reduction in loss of RMB 19,635,000 compared to 2023[17]. - The basic loss per share for 2024 was approximately RMB 0.098, compared to RMB 0.130 for the year ended December 31, 2023[17]. - As of December 31, 2024, total assets were approximately RMB 206,138,000, down from RMB 254,190,000 in 2023[20]. - The current ratio decreased to approximately 0.73 from 0.91 in the previous year, primarily due to an increase in borrowings of about RMB 26,763,000[20]. Revenue Breakdown - Printer business revenue was approximately RMB 130,139,000, accounting for about 87% of total revenue, also down by approximately 26% year-on-year due to the promotion of electronic invoices in mainland China[11]. - Other product revenue was approximately RMB 19,598,000, representing about 13% of total revenue, which also decreased by approximately 26% due to reduced sales of medical products following the end of the pandemic[12]. Gross Profit and Margins - The gross profit margin increased to 12% due to a reduction in inventory provisions despite the overall operating loss[7]. - The gross profit margin increased from 11% in 2023 to 12% in 2024 due to a decrease in inventory provisions[18]. Future Plans and Product Development - The company plans to launch a cost-effective multifunctional inkjet printer and laser printer products in the second quarter of 2025[8]. - A smart cloud self-service delivery cabinet for logistics applications is expected to be launched in 2025[8]. - The company aims to develop a full range of portable oxygen machines with capacities from 3L to 15L, targeting the high-altitude oxygen subsidy policy set to be introduced by the government by the end of 2024[8]. - The company plans to launch a high-altitude oxygen machine in the first half of 2025, targeting the new national subsidy policy for high-altitude oxygen[16]. - New product launches include medical devices, inkjet printing, cloud printing, and self-service terminals, which are expected to aid in market transformation and capture[47]. Employee and Organizational Information - The group employed 572 staff as of December 31, 2024, down from 670 in the previous year[28]. - Employee satisfaction has been consistently above the target score of 87, with a score of 88.4 in 2024[52]. - The company has established a safety committee and implemented an occupational health and safety management system based on ISO45001 standards[197]. - Employee training facilities accommodate over 100 people, providing both online and offline training opportunities[200]. Corporate Governance - The company has complied with the corporate governance code, except for the chairman's absence at the annual general meeting due to other commitments[85]. - The board consists of two executive directors, one non-executive director, and three independent non-executive directors, ensuring a balanced skill set and experience necessary for the company's operations[101]. - The independent non-executive directors represent more than one-third of the board, allowing for independent opinions and guidance[101]. - The company has established mechanisms to ensure independent opinions are provided to the board, enhancing governance practices[101]. Environmental, Social, and Governance (ESG) Initiatives - The company has set specific ESG goals, including a 3% reduction in water usage compared to the previous year and achieving 100% certification for energy-efficient products[162]. - The company achieved a significant reduction in wastewater discharge, totaling 41,437 tons in 2024, down by 3,952 tons from 2023[181]. - The company reported that all emissions from its production processes met national standards, with particulate matter emissions at less than 20 mg/m³ in 2024, significantly lower than the reference limit of 120 mg/m³[179]. - The company has established an Environmental Management Team to oversee daily operations related to safety and environmental management[159]. Risk Management and Compliance - The company has a structured risk management framework to identify and assess significant risks affecting its operations[131]. - The company emphasizes compliance with relevant laws and regulations in both mainland China and Hong Kong, ensuring adherence to significant legal requirements[59]. - The company has established a comprehensive internal control department to investigate allegations and report findings to the board in real-time if criminal evidence is disclosed[151]. Shareholder Communication and Relations - The company emphasizes effective communication with shareholders to enhance investor relations and understanding of business performance and strategy[137]. - The company is committed to maintaining ongoing communication with shareholders, particularly through annual and special general meetings[137]. - The company ensures that all communications with shareholders are bilingual to facilitate understanding[140].
映美控股(02028) - 2024 - 年度业绩
2025-03-28 14:31
Financial Performance - For the fiscal year ending December 31, 2024, the total revenue was RMB 3,149,737 thousand, a significant increase from RMB 203,484 thousand in 2023[3] - The net loss for the year was RMB (60,262) thousand, an improvement from a net loss of RMB (79,793) thousand in 2023, reflecting a 24% reduction in losses[5] - Total revenue for the year ended December 31, 2024, was RMB 149,737,000, a decrease of 26.4% from RMB 203,484,000 in 2023[24] - The group reported a net loss of RMB 60,262,000 for the year ended December 31, 2024, compared to a net loss of RMB 79,793,000 in 2023, indicating an improvement of 24.5%[24] - The basic and diluted loss per share improved to RMB (0.098) from RMB (0.130) in the previous year[4] Revenue and Segments - Revenue from the printing machine segment decreased by approximately 26% due to the nationwide implementation of digital electronic invoices[16] - Revenue from external customers for the printer segment was RMB 130,139,000, down from RMB 176,848,000 in 2023, representing a decline of 26.4%[24][25] - For the fiscal year ending December 31, 2024, the company's revenue from the printer business was approximately RMB 130,139,000, accounting for about 87% of total revenue, a decrease of approximately 26% compared to 2023[42] - For the year ending December 31, 2024, the group's other products revenue was approximately RMB 19,598,000, accounting for about 13% of total revenue, a decrease of approximately 26% compared to 2023 due to reduced sales of medical products following the pandemic's decline[43] Expenses and Cost Management - The cost of goods sold decreased to RMB (131,363) thousand from RMB (180,961) thousand, resulting in a gross profit of RMB 18,374 thousand compared to RMB 22,523 thousand in the previous year[3] - Research and development expenses were reduced to RMB (15,064) thousand from RMB (20,615) thousand, indicating a 27% decrease year-over-year[3] - The company reported a significant decrease in administrative expenses to RMB (32,985) thousand from RMB (39,158) thousand, a reduction of about 16%[3] - The group’s sales and marketing expenses were RMB 27,123,000 in 2024, compared to RMB 30,985,000 in 2023, a reduction of 12.5%[24][29] - The total cost of goods sold and expenses recognized in 2024 was RMB 206,535,000, down from RMB 271,719,000 in 2023, a decrease of 24.0%[29] Assets and Liabilities - Total assets decreased to RMB 206,138 thousand from RMB 254,190 thousand, representing a decline of approximately 19%[6] - The company's total liabilities increased to RMB 196,807 thousand from RMB 177,415 thousand, marking an increase of about 11%[8] - The group's current liabilities exceeded current assets by approximately RMB 46,089,000 as of December 31, 2024[14] - The total accounts receivable as of December 31, 2024, was RMB 40,930,000, an increase from RMB 31,613,000 in 2023[38] - The total accounts payable as of December 31, 2024, was RMB 45,272,000, slightly up from RMB 44,746,000 in 2023[39] Financing and Cash Flow - The group has secured standby financing of RMB 35,000,000, including an unused amount of RMB 20,000,000, to ensure financial resources when needed[17] - The total bank borrowings amounted to approximately RMB 136,431,000, with RMB 112,431,000 due within 12 months[14] - Cash and cash equivalents decreased to RMB 24,434 thousand from RMB 37,291 thousand, a decline of approximately 34%[6] - The group’s borrowings increased to approximately RMB 140,797,000 from RMB 111,034,000 year-over-year[54] Corporate Governance and Compliance - The company has adhered to all corporate governance codes as per the Hong Kong Stock Exchange listing rules, except for the attendance of the chairman at the annual general meeting due to other business commitments[68] - The Audit Committee has reviewed the group's financial statements for the year ending December 31, 2024, ensuring completeness, accuracy, and fairness[67] - The company has fully complied with the standard code of conduct regarding director securities transactions for the year ending December 31, 2024[71] Future Outlook and Strategy - The group anticipates that domestic demand for printing machines will stabilize and plans to continue developing enhanced functionalities and expanding sales channels[17] - The company expects market demand to recover in 2025 due to government policies aimed at stimulating consumption and supporting manufacturing, alongside the gradual market introduction of medical products[44] - The company plans to launch a cloud printing machine for small and medium-sized wholesalers in 2024, facilitating remote printing and integrated management of store inventory[45] - The company plans to launch a high-altitude version of a specialized oxygen machine in the first half of 2025, in response to national policies on oxygen supplementation[49] Employee and Operational Metrics - The group employed 572 staff as of December 31, 2024, down from 670 employees in the previous year[62] - The company’s capital expenditures for the year ending December 31, 2024, were approximately RMB 1,797,000, primarily for the purchase of production equipment and product molds[52] Taxation - The corporate income tax rate for Jiangyu Information is 15% for the fiscal year ending December 31, 2024, down from 25% in 2023, due to its qualification as a high-tech enterprise[32] - The company’s income tax rate applicable in Hong Kong remains at 16.5% for both fiscal years 2024 and 2023[31]
映美控股(02028) - 2024 - 中期财报
2024-09-20 08:36
| --- | --- | |-------|-------| | | | | | | ● ● 目錄 2 公司資料 3 管理層討論與分析 9 中期財務資料審閱報告 11 簡明綜合中期資產負債表 13 簡明綜合中期收益表 14 簡明綜合中期全面收益表 15 簡明綜合中期權益變動表 16 簡明綜合中期現金流量表 17 簡明綜合中期財務資料附註 35 其他資料 公司資料 | --- | --- | |---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------| | | | | 董事 | 提名委員會 | | 執行董事 | 簡麗娟女士 (主席) | | 歐栢賢先生 (主席) 歐國倫先生 (行政總裁) | 孫寶源先生 楊國強先生 | | 非執行董事 | 核數師 | | 歐國良先生 | 羅兵咸永道會計師事務所 執業會計師 | | 獨立非執行董事 | ...
映美控股(02028) - 2024 - 中期业绩
2024-08-27 14:03
Financial Performance - The company's revenue for the six months ended June 30, 2024, was RMB 84,237,000, a decrease of 28.6% compared to RMB 117,988,000 for the same period in 2023[1]. - The gross loss for the period was RMB 3,973,000, compared to a gross profit of RMB 22,281,000 in the previous year, indicating a significant decline in profitability[1]. - Operating loss increased to RMB 38,530,000 from RMB 29,821,000 year-on-year, reflecting ongoing challenges in the business[2]. - The net loss attributable to shareholders for the period was RMB 43,406,000, compared to RMB 34,232,000 in the same period last year, representing a 27% increase in losses[2]. - The company reported a basic and diluted loss per share of RMB 0.071, compared to RMB 0.056 in the same period last year, reflecting worsening financial performance[2]. - For the six months ending June 30, 2024, the group recorded a loss of approximately RMB 43,495,000 and a net cash outflow from operating activities of approximately RMB 18,686,000[9]. - The group reported a loss of RMB 43,495 thousand for the six months ended June 30, 2024, compared to a loss of RMB 34,431 thousand for the same period in 2023[15]. - The comprehensive gross loss for the group was RMB 3,973,000, with a gross margin of -5%, primarily due to provisions for inventory impairment of approximately RMB 8,580,000 and long-term asset impairment of approximately RMB 17,692,000[39]. Assets and Liabilities - Total assets decreased to RMB 206,709,000 as of June 30, 2024, down from RMB 254,190,000 at the end of 2023, indicating a reduction in the company's asset base[4]. - The company's total liabilities were RMB 176,198,000, slightly down from RMB 177,415,000 at the end of 2023, showing a stable liability position[6]. - Cash and cash equivalents fell to RMB 27,539,000 from RMB 37,291,000, highlighting liquidity challenges[4]. - As of June 30, 2024, the group's current liabilities exceeded its current assets by approximately RMB 33,707,000[9]. - The company's current ratio was approximately 0.78 as of June 30, 2024, down from 0.91 as of December 31, 2023, due to a decrease in current assets of approximately RMB 17,107,000[41]. Revenue Segmentation - Revenue from the printer segment accounted for about 44% of total revenue for the six months ended June 30, 2024, compared to 19% for the same period in 2023[17]. - For the six months ended June 30, 2024, the company's revenue from printer business was approximately RMB 71,741,000, accounting for about 85% of total revenue, and decreased by approximately 31% compared to the same period in 2023[30]. - Revenue from other products for the same period was approximately RMB 12,496,000, representing about 15% of total revenue, and decreased by approximately 9% year-on-year, primarily due to the delayed market launch of medical products[31]. - The revenue from the printing machine segment decreased by 31% due to a decline in demand for needle printers, influenced by the nationwide implementation of digital electronic invoices[9]. Research and Development - Research and development expenses decreased to RMB 6,768,000 from RMB 11,644,000, suggesting a potential reduction in innovation efforts[1]. - The group incurred research and development expenses of RMB 6,768 thousand for the six months ended June 30, 2024, compared to RMB 5,452 thousand for the same period in 2023[14]. - The company has developed a series of SaaS applications based on cloud printing, including "E Invoice" and "Reimbursement Without Worry," aimed at small and medium-sized enterprises[35]. Future Outlook and Strategies - The group anticipates that the domestic market demand for needle printers has stabilized and continues to develop enhanced functionalities for these printers[10]. - The group is optimistic about the sales potential and growth in the emerging consumer printing equipment market and medical device market, which is expected to provide additional cash inflow in 2024 and 2025[10]. - The company plans to strengthen the application of needle printers in manufacturing, e-commerce, logistics, and internal management of trade enterprises in the second half of 2024[32]. - The company aims to expand the market for medical device products in the second half of 2024[32]. - The company plans to launch the "PC Cloud Printer" in 2023, enhancing market competitiveness through cloud technology[33]. - The company is conducting clinical trials for a pulse oximeter expected to launch by the end of 2024, which will integrate oxygen generation and blood oxygen monitoring[37]. Cost Management - The group has implemented strict cost and expenditure control measures in the second quarter of 2024 to reduce operating cash outflows[11]. - The company has implemented cost-saving measures that are projected to reduce expenses by E million annually[52]. Corporate Governance and Compliance - The company has maintained compliance with corporate governance codes, with a noted absence of the chairman at the annual general meeting due to other business commitments[49]. - The interim financial information for the six months ended June 30, 2024, has been reviewed by the audit committee and independent auditors[51]. Employee and Dividend Information - The total number of employees as of June 30, 2024, is 621, a decrease from 670 employees as of December 31, 2023[46]. - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2024[25].
映美控股(02028) - 2023 - 年度财报
2024-04-26 10:47
Financial Performance - The company recorded revenue of approximately RMB 203,484,000 in 2023, a decrease of about 27% compared to 2022, with a net loss attributable to shareholders of approximately RMB 79,469,000[6]. - Revenue from the printer business was approximately RMB 176,848,000, accounting for about 87% of total revenue, which represents a decrease of approximately 30% year-on-year[11]. - Revenue from other products was approximately RMB 26,636,000, accounting for about 13% of total revenue, showing an increase of approximately 3% due to higher sales of medical products[12]. - The gross profit margin declined to 11% in 2023, reflecting ongoing operational losses[6]. - The net loss attributable to shareholders was approximately RMB 79,469,000, an increase in loss of RMB 39,442,000 compared to 2022[21]. - The gross profit margin declined to 11% due to inventory impairment provisions and long-term asset impairment provisions[22]. - As of December 31, 2023, total assets were approximately RMB 254,190,000, down from RMB 356,597,000 in 2022[24]. - The company had cash and cash equivalents of approximately RMB 37,291,000, a decrease from RMB 68,974,000 in the previous year[26]. - The company’s leverage ratio increased to 42.8% as of December 31, 2023, compared to 33.3% in the previous year[26]. Product Development and Innovation - The company has developed portable medical oxygen machines (5L and 7L), with the 7L model already registered for sale in the domestic market[6]. - The company is expanding its product offerings, including new inkjet printers tailored for the medical sector and cloud printing solutions[14]. - The company has launched several SAAS applications, including "E开单" for remote printing and "报销无忧" for online reimbursement processes[17]. - The company is focusing on integrating hardware and software products to provide digital invoice services for various industries[14]. - The company aims to enhance its market competitiveness through the introduction of cloud printing technology and new product lines[14]. - The company completed the development of equivalent 5L and 7L portable medical oxygen concentrators, with the 7L model receiving certification in December 2023[20]. - The company plans to develop a 10L portable medical oxygen concentrator and a low-noise 5L remote-controlled oxygen concentrator for severe patients in 2024[20]. - New product certifications achieved in 2023 include a small molecular sieve oxygen generator, which has commenced mass production[66]. Market Outlook and Strategy - Future business outlook remains positive, with expectations of government policies to stimulate consumption and support manufacturing, potentially restoring market demand[13]. - The company is focusing on developing cloud printing technology and launching various products suitable for electronic invoicing to meet market demands[52]. - The company plans to position itself as a cloud application service provider, expanding printing equipment applications and offering integrated online and offline retail solutions[53]. - The company is actively developing new products in sectors such as medical devices, inkjet printing, and self-service terminals to enhance market presence[55]. - The company aims to enhance its product core technology and expand sales channels to maintain reasonable profit levels amid intense competition[57]. Corporate Governance and Compliance - The company is committed to maintaining high corporate governance standards and has complied with the relevant rules of the Hong Kong Stock Exchange for the year ending December 31, 2023[102]. - The board of directors includes experienced professionals with diverse backgrounds in finance, technology, and management, contributing to the company's strategic direction[109]. - The company has adopted the corporate governance code and complied with all relevant provisions for the year ended December 31, 2023[119]. - The company has mechanisms in place to ensure independent opinions and contributions from independent non-executive directors, who constitute more than one-third of the board[129]. - The company aims to enhance investor confidence and accountability through strict corporate governance practices[102]. Employee and Stakeholder Engagement - Employee satisfaction score reached 92.9 in 2023, maintaining above 90 for several years[61]. - The company implemented a salary adjustment in January 2023, alongside an annual bonus scheme based on operational performance[62]. - The company contributes 14% of employee salaries to the retirement benefit fund for its Chinese subsidiaries[88]. - In Hong Kong, the company contributes 5% of each employee's monthly salary to the Mandatory Provident Fund, with a cap of HKD 1,500 per employee[88]. - The company aims to enhance shareholder communication and participation through its corporate governance structure[158]. - The company is committed to maintaining effective communication with shareholders to enhance long-term value[162]. Environmental and Social Responsibility - The company has established a comprehensive ESG management focus, including improving environmental performance and promoting a diverse workplace culture[198]. - The company achieved a 100% rating for energy efficiency labels on its printer products[191]. - Water consumption was reduced by 3% compared to the previous year[191]. - The total amount of non-hazardous waste emissions decreased by 5% year-on-year[191]. - The company has set a goal to ensure 100% of hazardous waste is handled by qualified recyclers[191]. - The group is committed to sustainable development and corporate social responsibility, integrating these principles into its operational planning[186]. Risk Management - The company has identified several key risks, including policy risks related to tax regulations affecting sales of impact printers[52]. - The company is addressing supply chain risks by signing quality assurance agreements with suppliers and managing procurement and production plans[56]. - The group has established a comprehensive internal control and risk management system to safeguard assets and ensure the reliability of financial data[155]. - The board has confirmed that the risk management and internal control systems are adequate and effective, complying with corporate governance codes[156]. Shareholder Information - The company did not recommend the payment of a final dividend for the year ending December 31, 2023, consistent with the previous year[36]. - As of December 31, 2023, the company's distributable reserves amounted to approximately RMB 226,428,000[46]. - The total number of shares available for issuance under the 2015 Plan is 60,481,950 shares, equivalent to 10% of the issued shares at the time of adoption[73]. - As of December 31, 2023, there are 1,600,000 unexercised options remaining from the 2020 grant, representing 0.26% of the issued share capital[75]. - The exercise price for the options granted in 2020 is set at HKD 0.130 per share[77]. - The 2015 Plan will remain effective until May 17, 2025, unless terminated by a resolution at a shareholders' meeting[73].
映美控股(02028) - 2023 - 年度业绩
2024-04-02 04:01
Financial Performance - Total revenue for the year 2023 was RMB 203,484,000, a decrease of 27.5% compared to RMB 279,191,000 in 2022[3] - Gross profit for 2023 was RMB 22,523,000, with a gross margin of approximately 11.1%[3] - The net loss for the year 2023 was RMB 79,793,000, compared to a net loss of RMB 40,009,000 in 2022, representing a 99.4% increase in losses[4] - Basic and diluted loss per share for 2023 was RMB 0.130, compared to RMB 0.065 in 2022, indicating a 100% increase in loss per share[4] - Total revenue for the year ended December 31, 2023, was approximately RMB 203.484 million, a decrease of 27% from RMB 279.191 million in 2022[30] - The group reported a net loss of RMB 79.793 million for the year ended December 31, 2023, compared to a net loss of RMB 40.009 million in 2022[30] - The company's pre-tax loss for 2023 was RMB 75,650,000, compared to a loss of RMB 35,075,000 in 2022, indicating a significant increase in losses[38] - The loss attributable to shareholders was approximately RMB 79,469,000, an increase in loss of RMB 39,442,000 compared to 2022[63] Assets and Liabilities - Total assets decreased to RMB 254,190,000 in 2023 from RMB 356,597,000 in 2022, a decline of 28.8%[8] - Total liabilities decreased to RMB 177,415,000 in 2023 from RMB 200,522,000 in 2022, a reduction of 11.5%[10] - The group’s current liabilities exceeded its current assets by approximately RMB 13,243,000 as of December 31, 2023[17] - Total bank borrowings amounted to approximately RMB 108,749,000, with RMB 87,224,000 due within the next 12 months[17] - Cash and cash equivalents decreased to RMB 37,291,000 in 2023 from RMB 68,974,000 in 2022, a decline of 46.0%[8] - The group reported a net cash outflow from operating activities of about RMB 19,599,000 for the year ended December 31, 2023[17] Revenue Segments - Revenue from external customers in the printer segment was RMB 176.848 million, accounting for about 87% of total revenue, down from RMB 253.273 million in 2022[32] - The revenue from the printing machine segment decreased by 30% due to a significant reduction in demand for needle printers following the nationwide implementation of digital electronic invoices[18] - Other products generated revenue of approximately RMB 26,636,000, representing about 13% of total revenue, an increase of approximately 3% compared to 2022, primarily driven by increased sales of medical products[51] - The printer business generated revenue of approximately RMB 176,848,000, accounting for about 87% of total revenue, a decrease of approximately 30% compared to 2022 due to the nationwide implementation of digital electronic invoices and insufficient market demand[50] Expenses - Research and development expenses increased to RMB 27,978,000 in 2023 from RMB 20,615,000 in 2022, an increase of 35.6%[3] - Administrative expenses increased slightly to RMB 39.158 million in 2023 from RMB 38.600 million in 2022[30] - The group reported a total of RMB 271.719 million in expenses for the year, a decrease from RMB 313.561 million in the previous year[36] - The group incurred financing costs of RMB 5.715 million, down from RMB 6.242 million in 2022[37] - The total income tax expense for 2023 was RMB 4,143,000, a decrease from RMB 4,934,000 in 2022, showing a reduction of approximately 16%[38] Market Outlook and Strategy - The group plans to expand its product offerings in emerging consumer printing equipment and medical device markets, expecting additional cash inflow in 2024[20] - The company anticipates a continued decline in printer demand due to the promotion of electronic invoices, but expects recovery in market demand in 2024 supported by government policies to stimulate consumption and the introduction of new medical products[52] - The company has developed new inkjet printers targeting the medical industry and launched a cloud printing machine that enhances market competitiveness[54] - The company plans to develop a 10L portable medical oxygen machine and a low-noise remote-controlled 5L oxygen machine in 2024[61] - The company is focusing on integrating software and hardware products to provide digital electronic invoice services for industries like catering and retail[54] Corporate Governance - The board believes that the group will have sufficient financial resources to meet its operational funding needs for at least the next 12 months[20] - The company did not declare any dividends for the year ending December 31, 2023, consistent with the previous year[45] - The board of directors did not recommend a final dividend for the year ended December 31, 2023, consistent with the previous year[80] - The company has established a share option scheme to reward and motivate employees[78] - The audit committee reviewed the group's performance for the year ended December 31, 2023[87] - The company has complied with all corporate governance codes except for the attendance of the chairman at the annual general meeting due to other business commitments[88] Employee and Operational Changes - As of December 31, 2023, the group employed 670 staff, a decrease from 768 staff in 2022[78] - Strict cost and expense control measures have been implemented to reduce operating cash outflow[20] - The accounts payable to third parties decreased from RMB 32,593,000 in 2022 to RMB 27,978,000 in 2023, indicating improved cash flow management[48] - The accounts payable aged less than 30 days decreased significantly from RMB 18,278,000 in 2022 to RMB 8,235,000 in 2023, reflecting better payment practices[48] Reporting and Compliance - The annual performance announcement and annual report will be published on the Hong Kong Stock Exchange website and the company's website[93] - The annual report for the year ending December 31, 2023, will be sent to shareholders and made available for viewing on the aforementioned websites[93] - The report will include all information required by the listing rules[93] - The company is committed to ensuring the accuracy of the information provided in the report[93] - The report will detail the company's financial performance and future outlook[93] - The company will focus on market expansion and new strategies in the upcoming year[93] - The company aims to enhance its product and technology development initiatives[93]
映美控股(02028) - 2023 - 年度业绩
2024-03-28 13:48
Financial Performance - Total revenue for the year 2023 was RMB 203,484,000, a decrease of 27.2% compared to RMB 279,191,000 in 2022[3] - Gross profit for 2023 was RMB 22,523,000, compared to RMB 65,099,000 in 2022, reflecting a significant decline[3] - Operating loss for 2023 was RMB 66,318,000, an improvement from the operating loss of RMB 28,589,000 in 2022[3] - Net loss attributable to shareholders for 2023 was RMB 79,469,000, compared to RMB 40,027,000 in 2022, indicating a worsening financial performance[4] - Basic and diluted loss per share for 2023 was RMB 0.130, compared to RMB 0.065 in 2022[4] - The group reported a net loss of RMB 79.793 million for the year ended December 31, 2023, compared to a net loss of RMB 40.009 million in 2022[30] - The company's pre-tax loss for 2023 was RMB 75,650,000, compared to a loss of RMB 35,075,000 in 2022, indicating a significant increase in losses[38] - The basic and diluted loss per share for 2023 was RMB 0.130, compared to RMB 0.065 in 2022, reflecting a 100% increase in loss per share[44] - The loss attributable to shareholders was approximately RMB 79,469,000, an increase in loss of RMB 39,442,000 compared to 2022[63] Assets and Liabilities - Total assets decreased to RMB 254,190,000 in 2023 from RMB 356,597,000 in 2022, a decline of 28.8%[8] - Total liabilities decreased to RMB 177,415,000 in 2023 from RMB 200,522,000 in 2022, a reduction of 11.5%[10] - Cash and cash equivalents decreased to RMB 37,291,000 in 2023 from RMB 68,974,000 in 2022, a decline of 46.0%[8] - Inventory decreased to RMB 70,098,000 in 2023 from RMB 101,399,000 in 2022, a reduction of 30.8%[8] - The group's current liabilities exceeded its current assets by approximately RMB 13,243,000 as of December 31, 2023[17] - The total bank borrowings amounted to approximately RMB 108,749,000, with RMB 87,224,000 due within the next 12 months[17] Research and Development - The company reported a significant increase in research and development expenses, rising to RMB 27,978,000 in 2023 from RMB 20,615,000 in 2022[3] - Research and development expenses totaled RMB 20.615 million, compared to RMB 27.978 million in 2022, indicating a reduction in investment in this area[30] - The company has developed new inkjet printers targeting the medical industry, including dual-color inkjet printers and specialized printing solutions for government and enterprise sectors[53] - The company launched a cloud printing machine in 2023, enhancing the competitiveness of its traditional printers by upgrading them to cloud printing capabilities[54] - The company has introduced various self-service terminal products, utilizing unique core technologies in smart governance and healthcare sectors[55] - The company has successfully obtained medical registration for a portable oxygen concentrator, which is designed for patients with respiratory issues, featuring advanced technology for oxygen delivery[59] Market and Sales - The revenue from the printing machine segment decreased by 30% due to a significant reduction in demand for needle printers following the nationwide implementation of digital electronic invoices[18] - Revenue from external customers in the printer segment was RMB 176.848 million, accounting for about 87% of total revenue, down from RMB 253.273 million in 2022[32] - The printer business generated revenue of approximately RMB 176,848,000, accounting for about 87% of total revenue, a decrease of approximately 30% compared to 2022 due to the nationwide implementation of digital invoices and insufficient market demand[50] - Other products generated revenue of approximately RMB 26,636,000, accounting for about 13% of total revenue, an increase of approximately 3% compared to 2022, primarily driven by increased sales of medical products[51] - The company anticipates that the demand for invoice printers will continue to decline in 2024 due to the promotion of electronic invoices, but expects market demand to recover with government policies to stimulate consumption and support manufacturing[52] - The group is optimistic about the sales potential and growth in the emerging markets, which is expected to contribute stable cash inflow in 2024[21] Cost Management - Strict cost and expense control measures were implemented in the last quarter of 2023 to reduce operating cash outflow[20] - Administrative expenses for the year were RMB 39.158 million, slightly increased from RMB 38.600 million in the previous year[30] - Financing costs decreased to RMB 5.715 million in 2023 from RMB 6.242 million in 2022, reflecting a reduction in interest expenses[37] Corporate Governance and Compliance - The group did not recommend a final dividend for the year ended December 31, 2023, consistent with the previous year[80] - The group has implemented a share option plan to reward and motivate employees[78] - The audit committee has reviewed the group's performance for the year ended December 31, 2023[87] - The company has complied with the corporate governance code, except for the chairman's absence at the annual general meeting due to other business commitments[88] - There were no significant events affecting the group after December 31, 2023, up to the announcement date[79] Employment and Workforce - As of December 31, 2023, the group employed 670 staff, a decrease from 768 staff in 2022[78]
映美控股(02028) - 2023 - 中期财报
2023-09-22 08:43
Revenue Performance - The printer business generated approximately RMB 104,227,000 in revenue, accounting for about 88% of total revenue, representing a decrease of approximately 25% compared to the same period in 2022 due to sluggish demand in the Chinese market[7]. - Revenue from other products reached approximately RMB 13,761,000, making up about 12% of total revenue, which is an increase of approximately 6% year-on-year, primarily driven by increased sales of medical products[8]. - For the six months ended June 30, 2023, the group's revenue was approximately RMB 117,988,000, a decrease of about 22% compared to the same period last year[18]. - Revenue for the six months ended June 30, 2023, was RMB 117,988,000, a decrease of 22.3% compared to RMB 151,755,000 in the same period of 2022[44]. - Revenue from the printer segment was RMB 104,227,000, down from RMB 138,818,000 in the previous year, representing a decline of 25%[71]. Financial Losses - The loss attributable to shareholders for the first half of 2023 was approximately RMB 34,232,000, compared to a loss of approximately RMB 9,554,000 in the first half of 2022[18]. - The net loss for the period was RMB 34,431,000, significantly higher than the net loss of RMB 9,573,000 in the prior year[44]. - For the six months ended June 30, 2023, the company reported a loss attributable to shareholders of RMB 34,232,000, compared to a loss of RMB 9,554,000 for the same period in 2022, representing an increase in loss of 258%[104]. - The basic and diluted loss per share for the six months ended June 30, 2023, was RMB 0.056, compared to RMB 0.016 for the same period in 2022, indicating a deterioration in performance[104]. Gross Profit and Margins - The comprehensive gross profit margin decreased to 19% due to impairment provisions for printer-related assets[19]. - Gross profit for the same period was RMB 22,281,000, down 48.3% from RMB 42,918,000 year-on-year[44]. Cash Flow and Assets - Cash and cash equivalents totaled approximately RMB 89,203,000 as of June 30, 2023, compared to RMB 68,974,000 as of December 31, 2022[23]. - Operating cash flow generated was RMB 1,683,000, a significant improvement from a cash outflow of RMB 60,055,000 in the same period last year[51]. - Total assets were approximately RMB 348,373,000, down from RMB 356,597,000 as of December 31, 2022[22]. - Total liabilities increased to RMB 225,518,000 as of June 30, 2023, from RMB 200,522,000 at the end of 2022[44]. Operational Developments - The company plans to launch a "PC Cloud Printer" in Q3 2023, enhancing the competitiveness of its traditional printers by upgrading them to cloud printers[12]. - The company has developed a series of medical devices, including a portable medical oxygen concentrator and a medical nebulizer, with plans to launch new models by the end of 2023 and mid-2024[15][17]. - The company is focusing on expanding its cloud printing services and has launched several SaaS applications, including "E Invoice" and "Reimbursement Without Worry" systems[14]. - The company has made significant progress in the inkjet printing sector, developing specialized printers for various industries, including healthcare and government[10]. Market Outlook - The company anticipates that the Chinese government's upcoming consumer stimulus and manufacturing support policies will help restore economic activity in the second half of 2023, boosting business confidence[9]. - The overall market outlook remains cautious due to reduced retail and business activities, but the introduction of new medical products is expected to support future growth[9]. Corporate Governance and Compliance - The company has maintained high corporate governance standards and has fully complied with the relevant regulations during the reporting period[129]. - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited interim financial information for the six months ending June 30, 2023[131]. - The company has complied with the corporate governance code, except for the absence of the chairman at the annual general meeting due to other business commitments[128]. Shareholder Information - The company’s major shareholder, Mr. Au Pak Yin, held 445,027,533 shares, representing 72.61% of the total issued shares as of June 30, 2023[116]. - Major shareholder Jiang Yu Holdings owns 445,027,533 shares, representing approximately 72.61% of the company's equity[118]. - Kent C. McCarthy holds 31,200,000 shares, accounting for about 5.09% of the company's equity[118]. Taxation - The company is exempt from paying income tax in the Cayman Islands and the British Virgin Islands, which may provide a favorable tax environment for future operations[101][102]. - The company’s subsidiaries in mainland China are subject to a corporate income tax rate of 25%, with a reduced rate of 15% applicable to its main subsidiary due to its qualification as a high-tech enterprise[98].
映美控股(02028) - 2023 - 中期业绩
2023-08-29 13:48
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責,對其準確性或完整性亦不發表任何聲明,並明確表示,概不對因本公告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOLIMARK HOLDINGS LIMITED 映 美 控 股 有 限 公 司 (於開曼群島註冊成立之有限公司) (股份代號:2028) 截 至 二 零 二 三 年 六 月 三 十 日 止 六 個 月 中 期 業 績 公 告 未經審核綜合業績 映美控股有限公司(「本公司」)董事(「董事」)會(「董事會」)謹此宣佈,本公司及其 附屬公司(「本集團」)截至二零二三年六月三十日止六個月(「本期間」)之未經審 核綜合業績,連同去年同期的比較數字如下: 簡明綜合中期收益表 截至六月三十日止六個月 二零二三年 二零二二年 未經審核 未經審核 附註 人民幣千元 人民幣千元 ...